These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 34849012)
1. CSMD1 Mutation Related to Immunity Can Be Used as a Marker to Evaluate the Clinical Therapeutic Effect and Prognosis of Patients with Esophageal Cancer. Fan X; Song J; Fan Y; Li J; Chen Y; Zhu H; Zhang Z Int J Gen Med; 2021; 14():8689-8710. PubMed ID: 34849012 [TBL] [Abstract][Full Text] [Related]
2. Huang T; Liang Y; Zhang H; Chen X; Wei H; Sun W; Wang Y Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828321 [TBL] [Abstract][Full Text] [Related]
3. FAT3 Mutation Is Associated With Tumor Mutation Burden and Poor Prognosis in Esophageal Cancer. Guo Z; Yan X; Song C; Wang Q; Wang Y; Liu XP; Huang J; Li S; Hu W Front Oncol; 2021; 11():603660. PubMed ID: 33816234 [TBL] [Abstract][Full Text] [Related]
4. Identification of clinical prognostic features of esophageal cancer based on m6A regulators. Wang H; Zhang Y; Chen L; Liu Y; Xu C; Jiang D; Song Q; Wang H; Wang L; Lin Y; Chen Y; Chen J; Xu Y; Hou Y Front Immunol; 2022; 13():950365. PubMed ID: 36159855 [TBL] [Abstract][Full Text] [Related]
5. Construction and validation of a tumor mutational burden and immune-related prognostic model for predicting the prognosis of patients with lung squamous cell carcinoma. Zhou Y; Xu M; Zhao K; Liu B J Thorac Dis; 2023 Mar; 15(3):1319-1334. PubMed ID: 37065576 [TBL] [Abstract][Full Text] [Related]
6. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma. Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739 [TBL] [Abstract][Full Text] [Related]
7. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698 [TBL] [Abstract][Full Text] [Related]
8. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer. Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791 [No Abstract] [Full Text] [Related]
9. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma. Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978 [TBL] [Abstract][Full Text] [Related]
10. Effect of Wang Z; Hou H; Zhang H; Duan X; Li L; Meng L Am J Transl Res; 2022; 14(2):849-862. PubMed ID: 35273689 [TBL] [Abstract][Full Text] [Related]
11. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079 [TBL] [Abstract][Full Text] [Related]
12. Characterization of the Immune Infiltration Landscape and Identification of Prognostic Biomarkers for Esophageal Cancer. Chen Y; Huang X; Chen L; Weng G; Huang Z; Zhang Y; Xiao T; Chen J; Zhu K; Xu Y Mol Biotechnol; 2023 Mar; 65(3):361-383. PubMed ID: 35780460 [TBL] [Abstract][Full Text] [Related]
13. CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma. Li Z; Feng Y; Li P; Wang S; Liu X; Xia S Int J Gen Med; 2022; 15():3809-3826. PubMed ID: 35418778 [TBL] [Abstract][Full Text] [Related]
14. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma. Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer. Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183 [TBL] [Abstract][Full Text] [Related]
16. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer. Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L Front Immunol; 2022; 13():943389. PubMed ID: 36003381 [TBL] [Abstract][Full Text] [Related]
17. The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients. Cui S; Feng J; Tang X; Lou S; Guo W; Xiao X; Li S; Chen X; Huan Y; Zhou Y; Xiao L Eur J Med Res; 2023 Feb; 28(1):90. PubMed ID: 36805828 [TBL] [Abstract][Full Text] [Related]
18. Identification and validation of necroptosis-related prognostic gene signature and tumor immune microenvironment infiltration characterization in esophageal carcinoma. Sun K; Hong JJ; Chen DM; Luo ZX; Li JZ BMC Gastroenterol; 2022 Jul; 22(1):344. PubMed ID: 35840882 [TBL] [Abstract][Full Text] [Related]
19. Identifying Xiang X; Gao LM; Zhang Y; Zhu Q; Zhao S; Liu W; Ye Y; Tang Y; Zhang W PeerJ; 2023; 11():e16618. PubMed ID: 38099311 [TBL] [Abstract][Full Text] [Related]
20. Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Model for Lower-Grade Glioma. Yin W; Jiang X; Tan J; Xin Z; Zhou Q; Zhan C; Fu X; Wu Z; Guo Y; Jiang Z; Ren C; Tang G Front Oncol; 2020; 10():1409. PubMed ID: 32974146 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]